Drug Shortage Report for ETOPOSIDE INJECTION USP
| Report ID | 65770 |
| Drug Identification Number | 02380935 |
| Brand name | ETOPOSIDE INJECTION USP |
| Common or Proper name | ETOPOSIDE |
| Company Name | SANDOZ CANADA INCORPORATED |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | ETOPOSIDE |
| Strength(s) | 20MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS |
| Packaging size | 50ML x 1VIAL |
| ATC code | L01CB |
| ATC description | PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS |
| Reason for shortage | Requirements related to complying with good manufacturing practices. |
| Anticipated start date | |
| Actual start date | 2018-12-17 |
| Estimated end date | 2022-06-27 |
| Actual end date | 2022-07-13 |
| Shortage status | Resolved |
| Updated date | 2022-07-14 |
| Company comments | Product is no longer marketed |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 4600 RUE ARMAND-FRAPPIER SAINT-HUBERT, QUEBEC CANADA J3Z 1G5 |
| Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.